CJC-1295 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-07 and is reviewed periodically as new material appears.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
== Bayesian inference of phylogeny background and bases == Bayesian inference refers to a probabilistic method developed by Reverend Thomas Bayes based on Bayes' theorem. Published posthumously in 1763 it was the first expression of inverse probability and the basis of Bayesian inference. Independently, unaware of Bayes' work, Pierre-Simon Laplace developed Bayes' theorem in 1774. Bayesian inference or the inverse probability method was the standard approach in statistical thinking until the early 1900s before RA Fisher developed what's now known as the classical/frequentist/Fisherian inference. Computational difficulties and philosophical objections had prevented the widespread adoption of the Bayesian approach until the 1990s, when Markov Chain Monte Carlo (MCMC) algorithms revolutionized Bayesian computation. The Bayesian approach to phylogenetic reconstruction combines the prior probability of a tree P(A) with the likelihood of the data (B) to produce a posterior probability distribution on trees P(A|B). The posterior probability of a tree will be the probability that the tree is correct, given the prior, the data, and the correctness of the likelihood model. MCMC methods can be described in three steps: first using a stochastic mechanism a new state for the Markov chain is proposed. Secondly, the probability of this new state to be correct is calculated. Thirdly, a new random variable (0,1) is proposed. If this new value is less than the acceptance probability the new state is accepted and the state of the chain is updated.
As an integral component of the Barshop Institute's comprehensive research training portfolio, UT-MSTAR complements the Institute's graduate and postdoctoral training programs while expanding opportunities for early-career investigators to enter the field of aging research.
When coarse-graining is done at higher levels, the accuracy of the dynamic description may be less reliable. But very coarse-grained models have been used successfully to examine a wide range of questions in structural biology, liquid crystal organization, and polymer glasses. Examples of applications of coarse-graining:
The Library of Congress is physically housed in three buildings on Capitol Hill and a conservation center in rural Virginia. The library's Capitol Hill buildings are all connected by underground passageways, so that a library user need pass through security only once in a single visit. The library also has off-site storage facilities in Maryland for less commonly requested materials.
=== Inhibitors === Ferroptosis can be inhibited by lipophilic radical trapping antioxidants such as ferrostatin-1, liproxstatin-1, and vitamin E. Chelation of iron by agents such as desferrioxamine mesylate (DFO) also prevents lipid peroxidation and suppresses ferroptosis.
Sources: en.wikipedia.org
=== Gene expression modulation and epigenetics === Apart from classical pharmacological targets, drugs may exert effects through direct or indirect gene expression modulation, or even introduce persistent state changes through epigenetic reprogramming. Therefore, drugs should be screened for off-target activity by gene expression profiling, in addition to conventional ligand binding, enzyme assays, etc.
=== Stable isotopes === The first evidence for multiple isotopes of a stable (non-radioactive) element was found by J. J. Thomson in 1912/1913 as part of his exploration into the composition of canal rays (positive ions). Thomson channelled streams of ions through parallel magnetic and electric fields, measured their deflection by placing a photographic plate in their path, and computed their mass to charge ratio using a method that became known as the Thomson's parabola method. Each 'line' could be identified with a specific atomic weight, and therefore different elements and compounds could be identified. Thomson's initial paper in the Philosophical Magazine explains the technique used, but makes no comment on anomalous lines; however, in a talk given to the Royal Institution on 17 January 1913 Thomson identified "a line corresponding to an atomic weight 22, which can not be identified with the line due to any known gas". He went on to comment thatThe origin of this line presents many points of interest; there are no known gaseous compounds of any of the recognized elements which have this molecular weight. Again, if we accept Mendeleef's Periodic Law, there is no room for a new element with this atomic weight.The same lecture was then given to the Cambridge Philosophical Society on 27 January 1913, and later in the year Thomson presented his mature interpretation as the Royal Society's Bakerian Lecture.
=== 21st century === In 2001, UPS acquired Mail Boxes Etc., Inc., a franchised network of packing and shipping retail centers across the United States and Canada. In 2003, the company rebranded the Mail Boxes, Etc. network as The UPS Store. In 2004, UPS entered the heavy freight business with the purchase of Menlo Worldwide Forwarding, a former subsidiary of Menlo Worldwide; UPS rebranded it as UPS Supply Chain Solutions. The purchase price was US$150 million and the assumption of US$110 million in long-term debt. On August 5, 2005, UPS announced that it had completed its acquisition of less-than-truckload (LTL) trucking company Overnite Transportation for US$1.25 billion. This was approved by the FTC and Overnite shareholders on August 4, 2005. On April 28, 2006, Overnite officially became UPS Freight. In 2005, UPS offered non-stop delivery service between Guangzhou and the United States. On October 3, 2005, UPS completed the purchase of Lynx Express, one of the largest independent parcel carriers in the United Kingdom, for £55.5 million (US$97.1 million) after receiving approval for the transaction from the European Commission. The first joint package car center operation in Dartford, Kent, was opened in 2006. On August 28, 2007, United Parcel Service celebrated its 100th anniversary. All Nippon Airways, a Star Alliance member, and UPS formed a cargo alliance and codeshare agreement to transport member cargo in 2008, similarly to an airline alliance.
== Beginning of the war == On September 1, 1939, Hitler's Germany began its invasion of Poland, marking the beginning of World War II. On September 4, President Lázaro Cárdenas, faithful to Mexico's pacifist policy, declared neutrality in the European conflict, which was seen as a new kind of war. However, neutrality did not prevent the government from condemning aggression against the sovereignty of democratic nations. Mexico recognized the Polish government-in-exile, and in December 1939, it criticized the Soviet invasion of Finland. In 1940 and 1941, Mexico condemned the German invasions of Norway, the Netherlands, Belgium, Greece and Yugoslavia. Before the German aggression against Holland and Belgium, Cárdenas declared on May 13, 1940 that:
=== Phimosis === Dorsal slit has a long history as a treatment for adult phimosis, since compared with circumcision it was relatively easy to perform, did not risk damage to the frenulum, and before the invention of antibiotics was less likely to become infected. However, the literature often indicates that despite being "a simple operation" it was "not liked by some", or refers to the "untidy apron-like appearance" it could produce. Dorsal slit has become rare in Western countries as a treatment for phimosis. Standard guidelines suggest conservative approaches first and, should those fail, either circumcision or preputioplasty to both retain the foreskin and relieve the phimosis.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.